<DOC>
	<DOCNO>NCT01187017</DOCNO>
	<brief_summary>Background : - Severe aplastic anemia ( SAA ) lead problem bone marrow health result low blood cell count , require frequent transfusion . Standard initial treatment SAA involve injection antithymocyte globulin ( ATG ) plus cyclosporine ( CsA ) . Patients SAA respond initial treatment ATG ( refractory ) high risk die without additional treatment . In case , match bone marrow transplant donor well-defined standard therapy . In experience patient respond horse ATG + CsA , one-third patient re-treated rabbit ATG + CsA improve . Experience cyclophosphamide treatment refractory severe aplastic anemia suggest drug able improve blood count 50 % case . However , cyclophosphamide regimen associate significant infection risk ( mostly cause fungus ) study conduct 10 year ago due lower white blood cell level . - Better antibiotic drug fungus develop widely use treat patient low white blood cell count risk develop infection . In SAA patient particular , new antibiotic large impact prevent treat fungus infection . Researchers revisit use cyclophosphamide lower dos minimize side effect give combination another immune suppressant , fludarabine . Objectives : - To determine safety effectiveness combination fludarabine plus cyclophosphamide treating severe aplastic anemia respond initial treatment .</brief_summary>
	<brief_title>A Pilot Study Fludarabine Plus Cyclophosphamide Refractory Severe Aplastic Anemia</brief_title>
	<detailed_description>Severe aplastic anemia ( SAA ) life-threatening bone marrow failure disorder characterize pancytopenia hypocellular bone marrow . Allogeneic hematopoietic stem cell transplantation ( HSCT ) offer opportunity cure 70 percent patient , patient suitable candidate treatment modality due advanced age , comorbidities lack histocompatible donor . For patient , comparable long-term survival attainable immunosuppressive treatment ( IST ) anti-thymocyte globulin ( ATG ) cyclosporine ( CsA ) . However , approximately 1/3 patient show blood count improvement ATG/CsA consider refractory disease . Furthermore , analysis extensive clinical data suggest poor blood count response single course ATG ( nonrobust responder ) , even transfusion-independence achieve , predicts markedly bad prognosis compare achieve robust hematologic improvement ( protocol 90-H-0146 ) . In patient refractory horse ATG ( h-ATG ) histocompatible sibling , alternative donor ( AD ) HSCT repeat course IST option . Registry data suggest outcome AD HSCT SAA favorable compare match sibling HSCT long-term survival 40-50 percent high risk graft-versus-host disease . However , recent small retrospective study survival AD HSCT child rival sibling transplant unrelated donor match 10 human leukocyte antigen ( HLA ) locus ( match unrelated donor ) available . With repeat IST , response rate rabbit anti-thymocyte varied 22 percent 77 percent . Our experience refractory SAA ( protocol 03-H-0249 ) rabbit ATG + CsA alemtuzumab equally efficacious salvage therapy , response rate 30 percent treatment . For 20-30 percent patient remain refractory 2 course treatment , course IST limit value response observe occasionally . In addition , effort improve initial IST treatment-na patient ( addition mycophenolate mofetil sirolimus ) yield promising regimen activity SAA ( protocols 00-H-0032 , 03-H-0193 , 06-H-0034 ) . Therefore , novel regimen need improve outcome SAA without histocompatible sibling , encompass majority patient disease . The current limitation IST SAA : 1 ) majority responses observe follow initial h-ATG/CsA partial patient achieve normal blood count ; 2 ) 1/3 patient refractory initial h-ATG/CsA ; 3 ) response rate refractory patient retreat 30 percent ; 4 ) hematologic relapse occur 35 percent responder follow initial response h-ATG/CsA ; 5 ) among relapsed patient chronic use CsA infrequent often lead toxicity long term exposure drug ( especially old patient ) ; 6 ) clonal evolution still observe 10-15 % patient . Towards goal address limitation propose novel regimen fludarabine ( Flu ) plus cyclophosphamide ( Cy ) SAA patient refractory horse ATG/CsA . The Hematology Branch considerable experience Flu/Cy part condition regimen allotransplantation protocol ( protocols 99-H-0050 , 97-H-0196 , 99-H-0064 , 99-H-0050 , 97-H-0196 , 02-H-0111 , 01-H0162 , 03-H-0192 , 04-H-0112 , 06-H-0248 , 07-H-0136 ) . In addition , regimen incorporate NCI 's Surgery Branch preparative regimen autologous HSCT prior infusion tumor infiltrate lymphocyte . Flu/Cy well tolerate potent immunosuppressive regimen myeloablative . Therefore , propose investigate Flu/Cy address current limitation IST SAA . The main objective study assess safety efficacy Flu/Cy refractory SAA . The primary endpoint hematologic response , define longer meet criterion SAA , 6 month . Secondary endpoint relapse , robustness hematologic recovery 6 month , response 3 month 12 month , survival , clonal evolution paroxysmal nocturnal hemoglobinuria ( PNH ) , myelodysplasia acute leukemia . The primary endpoint change absolute neutrophil count , platelet count , reticulocyte count 6 month . Secondary endpoint include time relapse , change cytogenetics , time death . Eligibility : - Individuals least 2 year age severe aplastic anemia improve treatment horse ATG horse rabbit ATG . Design : - After initial screening , medical history , blood test , participant admit inpatient unit National Institutes Health Clinical Center . - Participants receive 2 day cyclophosphamide , follow 5 day fludarabine . - Participants also receive antibiotic drug protect bacterial , fungal , viral infection . Participants take drug regularly white blood cell count improve . - After discharge clinical center , participant follow-up evaluation 3 month , 6 month , annually 5 year . Evaluations include blood sample periodic bone marrow biopsy .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Severe aplastic anemia characterize : Bone marrow cellularity &lt; 30 percent ( exclude lymphocyte ) AND At least two follow : Absolute neutrophil count &lt; 500/ microL Platelet count &lt; 20,000/ microL Absolute reticulocyte count &lt; 60,000/ microL 2 . Failure respond initial course hATG/CsA least 3 month posttreatment suboptimal response initial hATG/CsA define platelet reticulocyte count &lt; 50,000 /microL 3 month posttreatment OR 3 . Refractory SAA unresponsive horse rabbit ATGbased regimen 4 . Age great equal 2 year old 5 . Weight great equal 12 kg EXCLUSION CRITERIA : 1 . Diagnosis Fanconi anemia 2 . Cardiac ejection fraction &lt; 30 percent ( evaluated ECHO ) 3 . Evidence clonal hematologic bone marrow disorder cytogenetics . Patients presence trisomy 8 , loss Y del ( 20q ) exclude absence dysplastic change marrow . Patients severe neutropenia ( ANC &lt; 200 /microL ) exclude initially cytogenetics available pending . If evidence clonal disorder later identify , patient go study ) 4 . Prior immunosuppressive therapy high dose Cy 5 . Infection adequately control appropriate therapy 6 . Serologic evidence HIV infection 7 . Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient 's ability tolerate protocol therapy , death within 30 day likely 8 . Subjects cancer active chemotherapeutic treatment take drug hematological effect 9 . Current pregnancy unwillingness take oral contraceptive refrain pregnancy childbearing potential 10 . Not able understand investigational nature study give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>Aplastic Anemia</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Immunosuppressive Therapy</keyword>
	<keyword>T-Cells</keyword>
</DOC>